子分类：
- C12R1/47： ...白色链霉菌
- C12R1/48： ...抗生素链霉菌
- C12R1/485： ...金霉素链霉菌
- C12R1/49： ...金色链霉菌
- C12R1/50： ...比基尼链霉菌
- C12R1/51： ...纯白链霉菌
- C12R1/52： ...教酒链霉菌
- C12R1/525： ...淀粉酶产色链霉菌
- C12R1/53： ...菲律宾链霉菌
- C12R1/54： ...弗氏链霉菌
- C12R1/545： ...灰色链霉菌
- C12R1/55： ...吸水链霉菌
- C12R1/56： ...薰衣草链霉菌
- C12R1/565： ...林肯链霉菌
- C12R1/57： ...诺尔斯氏链霉菌
- C12R1/58： ...橄榄色链霉菌
- C12R1/585： ...普拉待链霉菌
- C12R1/59： ...龟裂链霉菌
- C12R1/60： ...产烯链霉菌
- C12R1/61： ...委内瑞拉链霉菌
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 221 | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same | US450639 | 1995-05-25 | US5496727A | 1996-03-05 | Masakuni Okuhara; Hirokazu Tanaka; Toshio Goto; Tohru Kino; Hiroshi Hatanaka |
| This invention relates to tricyclo compounds useful for treatment and prevention of resistance by transplantation, graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases, infectious diseases, and the like, which can be represented by the following formula: ##STR1## to a process for their production, to a pharmaceutical composition containing the same and to a use thereof. | ||||||
| 222 | Streptomyces braegensis strain and its cultivation in a process for producing C.sub.9 -desoxo-FK-520 | US129159 | 1994-01-24 | US5494820A | 1996-02-27 | Walter P. Cullen; Mark A. Guadliana; Liang H. Huang; Keiji Kaneda; Nakao Kojima; Gloria Kostek; Satoshi Nishiyama; Yuji Yamauchi; Yasuhiro Kojima |
| A compound of the formula ##STR1## is a novel immunosuppressant agent prepared by fermenting Steptomyces braeaensis subsp. pulcherrimus, ATCC 55150, or another compound of the formula I producing strain and extracting the compound of the formula I from the fermentation medium. The compound is useful in treating transplant rejection and autoimmune diseases. | ||||||
| 223 | Biodegradable azo dyes | US930162 | 1992-08-12 | US5486214A | 1996-01-23 | Andrzej Paszczynski; Stefan Goszczynski; Ronald L. Crawford; Donald L. Crawford; Maria B. Pasti |
| A biodegradable azo dye contains a nitrogen atom linked to an aromatic ring having a lignin-like substitution pattern. The ring is preferably a syringyl or guaiacol moiety, and provides a naturally-occurring structure for attack by microorganisms, such as Streptomyces or Phanerochaete. In especially preferred embodiments, the aromatic ring has a first substituent R.sub.1 selected from among hydroxy, lower alkoxy, or amino, and a second substituent R.sub.2 selected from among lower alkyl, lower alkoxy and halogen. Some embodiments include a third ring substituent R.sub.3 selected from the group lower alkyl, lower alkoxy, and halogen. | ||||||
| 224 | Compounds 31668P and 31668U, a process for their production and their use | US77985 | 1993-06-17 | US5459141A | 1995-10-17 | Laslo Vertesy; Joachim Betz; Hans-Wolfram Fehlhaber; Matthias Helsberg; Herbert Kogler; Michael Limbert; Dieter-Andreas Sukatsch; Ramaiyer R. Chandran; Bimal N. Ganguli |
| Compounds 31668P and 31668U, a process for their production and their use.Compound 31668P and compound 31668U with the formulae ##STR1## have an antibiotic and an antitumor action. | ||||||
| 225 | Process for the preparation of antiparasitic agents | US28459 | 1993-03-09 | US5451511A | 1995-09-19 | Stephen P. Gibson; Alexander C. Goudie; Kelvin S. Holdom; John D. Bu'Lock |
| The invention provides novel compounds having the formula: ##STR1## wherein R when taken individually is H; R.sup.1 when taken individually is H or OH; R and R.sup.1 when taken together represent a double bond;R.sup.2 is an alpha-branched C.sub.3 -C.sub.8 alkyl, alkenyl, alkynyl, alkoxyalkyl or alkylthioalkyl group; a C.sub.3 -C.sub.8 cycloalkyl, C.sub.5 -C.sub.8 cycloalkenyl or C.sub.5 -C.sub.8 cycloalkylalkyl group, any of which may be substituted by methylene or one or more C.sub.1 -C.sub.4 alkyl groups or halo atoms; or a 3 to 6 membered oxygen or sulphur containing heterocyclic ring which may be substituted by one or more C.sub.1 -C.sub.4 alkyl groups or halo atoms;R.sup.3 is hydrogen or methyl;R.sup.4 is H or 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy with the proviso that when R.sup.2 is alkyl it is not isopropyl or sec-butyl; when R.sup.4 is H, each of R and R.sup.1 is H, and R.sup.2 is not methyl or ethyl; and when R.sup.4 is H, R is H, R.sup.1 is OH, and R.sup.2 is not 2-buten-2-yl, 2-penten-2-yl or 4-methyl-2-penten-2-yl.The compounds are broad spectrum antiparasitic agents having utility as anthelmintics, ectoparasiticides, insecticides and acaricides. The invention also provides a process for producing the novel avermectin and milbemycin derivatives by adding a carboxylic acid or derivative thereof to a fermentation of an avermectin or milbemycin producing organism. | ||||||
| 226 | Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2 | US150639 | 1993-11-10 | US5426108A | 1995-06-20 | Joseph A. Zaccardi |
| This invention relates to antibiotic 31F508.alpha..sub.1 of the formula ##STR1## 31F508.alpha..sub.2, 31F508.beta..sub.1 and 31F508.beta..sub.2, derived from the microorganism Streptomyces viridodiastaticus subsp. "littus" which are useful as anti-bacterial agents. | ||||||
| 227 | Antibiotic AB-041 derived from Streptomyces sp. NCIMB 40428, herbicidal compositions, and methods of use | US983744 | 1992-12-01 | US5401709A | 1995-03-28 | Nunzio Andriollo; Alessandro Scacchi; Giorgio E. Borgonovi; Giorgio Cassani; Silvia Spera; Gianfranco Guglielmetti; Giorgio Pirali; Giovanni Confalonieri |
| The antibiotic AB-041 is described, obtained by controlled aerobic cultivation of Streptomyces sp. NCIMB 40428 in an aqueous culture medium. The antibiotic AB-041 exhibits biological activity, and in particular herbicidal activity. | ||||||
| 228 | Antibiotics AB-023 and process for preparing them | US136754 | 1993-10-15 | US5397570A | 1995-03-14 | Rossella Bortolo; Dante Cidaria; Giorgio Cassani; Adriana Vallesi; Gianfranco Gugliemetti; Giorgio Borgonovi; Silvia Spera; Giorgio Pirali; Giovanni Confalonieri |
| The Antibiotic Complex AB-023 and its components: Antibiotic AB-023a and ibiotic AB-023b are disclosed, which are obtained by the controlled aerobic culture of Streptomyces sp. NCIMB 40212 in an aqueous nutrient culture substrate. Antibiotics AB-023 display a biological activity against pathogen fungi which attack agricultural crops and man. | ||||||
| 229 | Compounds produced by a strain of Streptomyces exfoliatus | US16380 | 1993-02-11 | US5332574A | 1994-07-26 | Koko Sugawara; Koji Tomita; Michael R. Kozlowski; Yosuke Sawada |
| Disclosed are active compounds BU-4726G-A and BU-4726G-B which contain a quinone chromophore and hydroquinone chromophore, respectively. The compounds are produced by fermentation of Streptomyces exfoliatus AA4510. The compounds possess antimicrobial, and K.sub.ATP channel blocking activities. | ||||||
| 230 | Strain mass-producing .epsilon.-poly-L-lysine | US864183 | 1992-04-03 | US5294552A | 1994-03-15 | Jun Hiraki; Hiroshi Morita |
| The present invention provides mutants mass-producing .epsilon.PL which are obtained by mutation treatment of a strain producing .epsilon.PL. For using the mutants, the mutants are cultured in a cultivated medium, .epsilon.PL is mass-produced and stored in the culture solution, and the stored .epsilon.PL is collected from the solution. For producing .epsilon.PL, a strain which produces .epsilon.PL is mutation-treated, the obtained mutant is cultivated in a culture medium to which L-lysine or L-lysine and one or more sugars are added, .epsilon.PL is mass-produced and stored in the culture solution, and the stored .epsilon.PL is collected from the solution.The mutants producing .epsilon.PL in large quantities are preferably the mutants which have tolerance to an analogue of L-lysine of Streptomyces albulus subsp. lysinopolymerus No. 346-D strain and chloramphenicol-treated mutant of the same bacteria. | ||||||
| 231 | Streptomyces spectabilis strains employed for producing streptovaricin C | US872518 | 1992-04-23 | US5266484A | 1993-11-30 | Kaname Inoue; Motohide Yamazaki; Kanji Murofushi; Richard W. Armentrout |
| Disclosed is a method for selecting a mutant strain belonging to the genus Streptomyces which is a hyper-producer of Streptovaricin C superior to those know heretofore. This is accomplished by first subjecting a natural strain of Streptomyces spectabilis to conditions so as to isolate organisms which are streptovaricin resistant. The streptovaricin resistant organisms thus isolated are then subjected to mutagenesis and then cultured. The colonies which are asporogenous are individually cultured in fermentation batches such that the strains take the form of pellets of varying sizes and colors. From the batch having the most heterogeneous mixture of pellets, the smallest pellet or the pellet(s) having the deepest color (usually deep red or crimson) is isolated. We have discovered that the strain of this pellet has a high likelihood of being a hyperproducer of streptovaricin. The strain of this pellet may then be subjected to fermentation conditions to produce streptovaricin. The nutrient broth containing fumaric acid or water-soluble salts thereof, and adsorbent polymer beads and the streptovaricin produced are recovered in the usual manner. In another embodiment, the fermentation may be carried out in a nutrient broth wherein fumaric acid or its water-soluble salts are deliberately excluded to achieve even higher productivity. | ||||||
| 232 | Cultures for production of B avermectins | US660971 | 1991-02-26 | US5234831A | 1993-08-10 | Edmund W. Hafner; Kelvin S. Holdom; S. Edward Lee |
| Streptomyces avermitilis lacking branched-chain 2-oxo acid dehydrogenase activity and avermectin B O-methyltransferase activity, method for preparation thereof, and use thereof to produce natural and non-natural B avermectins useful as parasiticides. | ||||||
| 233 | Peptides WS-9326a and WS-9326b, derivatives thereof and uses thereof | US794698 | 1991-11-20 | US5217952A | 1993-06-08 | Tohru Kino; Motoaki Nishikawa; Masami Ezaki; Sumio Kiyoto; Masakuni Okuhara; Shigehiro Takase; Satoshi Okada; Nobuharu Shigematsu |
| This invention relates to the novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof which have pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain. | ||||||
| 234 | Process for preparing and selecting hyperproducing microorganism strains used for the process for producing streptovaricin C | US872519 | 1992-04-23 | US5210033A | 1993-05-11 | Kaname Inoue; Motohide Yamazaki; Kanji Murofushi; Richard W. Armentrout |
| Disclosed is a method for selecting a mutant strain belonging to the genus Streptomyces which is a hyper-producer of Streptovaricin C superior to those know heretofore. This is accomplished by first subjecting a natural strain of Streptomyces spectabilis to conditions so as to isolate organisms which are streptovaricin resistant. The streptovaricin resistant organisms thus isolated are then subjected to mutagenesis and then cultured. The colonies which are asporogenous are individually cultured in fermentation batches such that the strains take the form of pellets of varying sizes and colors. From the batch having the most heterogeneous mixture of pellets, the smallest pellet or the pellet(s) having the deepest color (usually deep red or crimson) is isolated. We have discovered that the strain of this pellet has a high likelihood of being a hyperproducer of streptovaricin. The strain of this pellet may then be subjected to fermentation conditions to produce streptovaricin. The nutrient broth containing fumaric acid or water-soluble salts thereof, and adsorbent polymer beads and the streptovaricin produced are recovered in the usual manner. In another embodiment, the fermentation may be carried out in a nutrient broth wherein fumaric acid or its water-soluble salts are deliberately excluded to achieve even higher productivity. | ||||||
| 235 | Process for producing FK-506 | US772520 | 1991-10-07 | US5194378A | 1993-03-16 | Gino M. Salituro; Francis Dumont; George M. Garrity; Leeyuan Huang; E. Tracy T. Jones; Mary N. Omstead; Isabel M. Fernandez; Teresa D. Matas |
| Described is a new process for producing the macrolide immunosuppressant, FK-506 under fermentation conditions utilizing the microorganism, Streptomyces sp., (Merck Culture Collection No. MA 6858) ATCC No. 55098. The immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants. | ||||||
| 236 | Process for the glycosylation of avermectin agylcones | US762183 | 1991-09-19 | US5188944A | 1993-02-23 | Mary N. Omstead; Marvin D. Schulman; Noel M. Young |
| Avermectin aglycones are glycosylated by fermentation in a medium of a non-producing mutant of Streptomyces avermitilis MA-6078. The glycosylation produces the monosaccharide and disaccharide derivatives while leaving the remainder of the molecule intact. The microorganism glycosylates with the .alpha.-L-oleandrose moiety. | ||||||
| 237 | Strains of Streptomyces thermoarchaensis | US480373 | 1990-02-14 | US5182207A | 1993-01-26 | John B. Ward; Hazel M. Noble; Neil Porter; Richard A. Fletton; David Noble |
| Compounds as described having the partial formula ##STR1## These compounds may have a 5-OH or --OMe group and at the 25- position an isopropylene group substituted by methyl, ethyl or isopropyl.The compounds may be used in agriculture or medicine as antiparasitics, and may be prepared by culturing certain Streptomyces strains, in particular Streptomyces thermoarchaensis NC1B 12015. | ||||||
| 238 | Microorganism employed for producing streptovaricin | US766412 | 1991-09-26 | US5177018A | 1993-01-05 | Kaname Inoue; Motohide Yamazaki; Richard W. Armentrout |
| A method for selecting hyper-producing strains of streptovaricin C by culturing streptomyces spectabilis and separating the asporogenous colonies. The asporogenous colonies are then separately cultured and tested for streptovaricin productivity. Those colonies having the highest productivity may then be easily selected. | ||||||
| 239 | Butalactin and its use as pharmaceutical | US563188 | 1990-08-06 | US5162368A | 1992-11-10 | Christopher M. M. Franco; Erra K. Vijayakumar; Sugata Chatterjee; Bimal N. Ganguli; Jurgen Blumbach |
| Butalactin, a compound of the formula I ##STR1## can be produced by cultivation of Streptomyces species Y-86,36923. Butalactin has an antibiotic activity. | ||||||
| 240 | Streptomyces parvullus DSM 3816 | US836533 | 1992-02-19 | US5158888A | 1992-10-27 | Peter Hammann; Susanne Grabley; Hartmut Voelskow; Burkhard Sachse; Wolfgang Raether; Carlo Giani; Gerhard Seibert |
| Streptomyces parvullus, DSM 3816, produces on aerobic fermentation new antibiotics which are distinguished by antimicrobial activity even after derivatization. | ||||||
QQ群二维码
意见反馈
意见反馈